AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19395187 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients with PRPH-PSA <=0.1 ng/ml
Number of subjects: 378
Study 19395187 — intervention group
Group type: COMPARATOR
Intervention: PRPH-PSA
Number of subjects: 378
Study 19395187 — intervention group
Group type: COMPARATOR
Intervention: Gleason score
Number of subjects: 378
Study 19395187 — intervention group
Group type: COMPARATOR
Intervention: Initial PSA
Number of subjects: 378
Study 19395187 — intervention group
Group type: COMPARATOR
Intervention: T-stage
Number of subjects: 378
Study 17297298 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule (Group C; N = 73, vaccination on days 0, 28 and 300)
Number of subjects: 294
Study 17297298 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified conventional schedule (Group M; N = 139, vaccination on days 0, 21 and 300)
Number of subjects: 294
Study 17297298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid schedule (Group R; N = 82, vaccination on Days 0, 7 and 21)
Number of subjects: 294
Study 16118920 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy (FT)
Number of subjects: 50
Study 16118920 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with deep nonperforative sclerectomy (FS)
Number of subjects: 50
Study 16118920 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with iridocleisis (FW)
Number of subjects: 50
Study 12832939 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive management
Number of subjects: 0
Study 12832939 — intervention group
Group type: EXPERIMENTAL
Intervention: Termination of pregnancy
Number of subjects: 0
Study 12832939 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective termination of multifetal pregnancies
Number of subjects: 0
Study 12832939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaggressive management
Number of subjects: 0
Study 12832939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalocentesis
Number of subjects: 0
Study 12832939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal research
Number of subjects: 0
Study 10575280 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary medical procedures
Number of subjects: 10
Study 10575280 — intervention group
Group type: COMPARATOR
Intervention: Health insurance reimbursement of complementary medical procedures
Number of subjects: 10
Study 10575280 — intervention group
Group type: COMPARATOR
Intervention: Cost developments
Number of subjects: 10
Study 8596594 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 583
Study 8596594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study 1785031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (1.0 watt/cm2 at 1 MHz, for 10 min) twice weekly for 8 weeks
Number of subjects: 38
Study 1785031 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound
Number of subjects: 38
Study 6101791 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leucocyte interferon (12 x 10(6) reference units daily for the first week, then halved weekly for six weeks)
Number of subjects: 16
Study 6101791 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leucocyte interferon
Number of subjects: 16
Study 6101791 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 patients not receiving interferon)
Number of subjects: 16
Study 31969362 — intervention group
Group type: EXPERIMENTAL
Intervention: CT group (offered annual CT screening, lung function test and smoking counselling)
Number of subjects: 4639
Study 31969362 — intervention group
Group type: COMPARATOR
Intervention: Control group (offered annual lung function test and smoking counselling)
Number of subjects: 4639
Study 29888943 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparing a present stimulus to a previously encountered source stimulus
Number of subjects: 0
Study 29888943 — intervention group
Group type: COMPARATOR
Intervention: Comparing two simultaneously present stimuli
Number of subjects: 0
Study 26687330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 8050
Study 26687330 — intervention group
Group type: COMPARATOR
Intervention: Standard Case Management (SCM)
Number of subjects: 8050
Study 24928217 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIMMER intervention (dietary and physical activity intervention, including case management and a maintenance programme)
Number of subjects: 0
Study 24928217 — intervention group
Group type: COMPARATOR
Intervention: Usual health care and written information about a healthy lifestyle (Control group)
Number of subjects: 0
Study 24928217 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIMMER intervention
Number of subjects: 0
Study 23265006 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased Reaction Time group
Number of subjects: 34
Study 23265006 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Reaction Time group
Number of subjects: 34
Study 23265006 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 20586550 — intervention group
Group type: COMPARATOR
Intervention: Tibolone (T)
Number of subjects: 0
Study 19014790 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive Patch (CP)
Number of subjects: 120
Study 19014790 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive Ring (CR)
Number of subjects: 120
Study 19014790 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CP vs CR at Cycle 4
Number of subjects: 120
Study 16292092 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable metallic stent
Number of subjects: 60
Study 16292092 — intervention group
Group type: COMPARATOR
Intervention: 3 x 7 Gy brachytherapy
Number of subjects: 60
Study 12023993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic oophorectomy
Number of subjects: 551
Study 12023993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic oophorectomy)
Number of subjects: 551
Study 10522500 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ascorbic acid (Cellex‐C high‐potency serum)
Number of subjects: 19
Study 10522500 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control serum
Number of subjects: 19
Study 8746883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily) + Calcium (1000 mg daily)
Number of subjects: 25
Study 8746883 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1000 mg daily)
Number of subjects: 25
Study 8746883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily)
Number of subjects: 25
Study 1838079 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol 1.5 mg on days 1‐12 and 17 beta‐oestradiol 1.5 mg + desogestrel 150 micrograms on days 13‐24 (E2/DG)
Number of subjects: 73
Study 1838079 — intervention group
Group type: EXPERIMENTAL
Intervention: oestradiol valerate 2 mg on days 1‐11 and oestradiol valerate 2 mg + medroxyprogesterone acetate 10 mg on days 12‐21 (E2V/MPA)
Number of subjects: 73
Study 1838079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 7193582 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine, 50 mg twice daily
Number of subjects: 34
Study 7193582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7193582 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 34
Study 31492178 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of pregnant women in clinical trials for pregnancy complications
Number of subjects: 0
Study 31492178 — intervention group
Group type: EXPERIMENTAL
Intervention: Research participation for unborn babies with complications
Number of subjects: 0
Study 31492178 — intervention group
Group type: EXPERIMENTAL
Intervention: Research participation for newborns
Number of subjects: 0
Study 28803030 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 118
Study 28803030 — intervention group
Group type: COMPARATOR
Intervention: Sham neurofeedback
Number of subjects: 118
Study 28803030 — intervention group
Group type: COMPARATOR
Intervention: Meta-cognitive therapy
Number of subjects: 118
Study 26109630 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus irinotecan (oral S-1 40-60 mg/m² on days 1-14 and intravenous irinotecan 150 mg/m² on day 1 of a 21-day cycle)
Number of subjects: 304
Study 26109630 — intervention group
Group type: COMPARATOR
Intervention: irinotecan-alone (intravenous irinotecan 150 mg/m² on day 1 of a 14-day cycle)
Number of subjects: 304
Study 26109630 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus irinotecan
Number of subjects: 304
Study 26109630 — intervention group
Group type: COMPARATOR
Intervention: irinotecan-alone
Number of subjects: 304
Study 23637556 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + Hydrochlorothiazide 25 mg (T80/H25)
Number of subjects: 0
Study 23637556 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 80 mg (T80)
Number of subjects: 0
Study 20499107 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Number of subjects: 43
Study 20499107 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 43
Study 20499107 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's symptoms
Number of subjects: 43
Study 20499107 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 43
Study 20499107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual bother
Number of subjects: 43
Study 19288570 — intervention group
Group type: EXPERIMENTAL
Intervention: FOBT (Hemoccult II) sensitivity at the stage of clinical diagnosis
Number of subjects: 3
Study 19288570 — intervention group
Group type: EXPERIMENTAL
Intervention: FOBT (Hemoccult II) sensitivity in earlier stages
Number of subjects: 3
Study 19288570 — intervention group
Group type: EXPERIMENTAL
Intervention: Average duration of preclinical CRC
Number of subjects: 3
Study 16678551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg per day for 5 days)
Number of subjects: 20
Study 16678551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15225889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine pretreatment via a transdermal patch (21 mg)
Number of subjects: 12
Study 15225889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol administration (0.4 and 0.7 g/kg)
Number of subjects: 12
Study 15225889 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 12
Study 11295031 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dialysis dose
Number of subjects: 0
Study 11295031 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dialysis dose
Number of subjects: 0
Study 11295031 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dialysis membrane flux
Number of subjects: 0
Study 11295031 — intervention group
Group type: EXPERIMENTAL
Intervention: High dialysis membrane flux
Number of subjects: 0
Study 11295031 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional monitoring by dietitian
Number of subjects: 0
Study 11295031 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional interventions
Number of subjects: 0
Study 9207355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorivudine 40 mg once daily for 7 days
Number of subjects: 125
Study 9207355 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 800 mg five times daily for 7 days
Number of subjects: 125
Study 8126036 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0‐millimeter orientruded polylactide screws (study group, n=83)
Number of subjects: 155
Study 8126036 — intervention group
Group type: COMPARATOR
Intervention: 4.0‐millimeter stainless‐steel screws (control group, n=72)
Number of subjects: 155
Study 2572205 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine plus neuroleptic
Number of subjects: 16
Study 2572205 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 30113736 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% clindamycin
Number of subjects: 100
Study 30113736 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% triple antibiotic paste (TAP)
Number of subjects: 100
Study 30113736 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% triple antibiotic paste (TAP)
Number of subjects: 100
Study 30113736 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 100
Study 30113736 — intervention group
Group type: COMPARATOR
Intervention: Methylcellulose (control)
Number of subjects: 100
Study 24458199 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg sustained-release tablet (SRT) of ONO-5334
Number of subjects: 33
Study 24458199 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dosing of 300-mg sustained-release tablet (SRT) of ONO-5334
Number of subjects: 33
Study 24458199 — intervention group
Group type: COMPARATOR
Intervention: 300-mg immediate-release tablet (IRT) of ONO-5334
Number of subjects: 33
Study 23111466 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic interviews conducted by two clinicians who were blind to previous diagnoses.
Number of subjects: 23
Study 23111466 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual clinical interview methods used for assessment.
Number of subjects: 23
Study 21435695 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF decompensation
Number of subjects: 11681
Study 21435695 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF compensation
Number of subjects: 11681
Study 21435695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic initiation
Number of subjects: 11681
Study 21435695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic discontinuation
Number of subjects: 11681
Study 18978621 — intervention group
Group type: EXPERIMENTAL
Intervention: Gymnasts
Number of subjects: 38
Study 18978621 — intervention group
Group type: COMPARATOR
Intervention: Male runners
Number of subjects: 38
Study 18978621 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gymnasts
Number of subjects: 38
Study 18978621 — intervention group
Group type: COMPARATOR
Intervention: Male controls
Number of subjects: 38
Study 18978621 — intervention group
Group type: COMPARATOR
Intervention: Female controls
Number of subjects: 38
Study 16814206 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental procedure (liquid‐based cytology and testing for high‐risk HPV types)
Number of subjects: 11810
Study 16814206 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing (> or = 1 pg/mL) with cytology triage
Number of subjects: 11810
Study 16814206 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid‐based cytology
Number of subjects: 11810
Study 16814206 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure (standard cytology)
Number of subjects: 11810
Study 12763513 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral hormone replacement therapy (HRT)
Number of subjects: 0
Study 12763513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10721594 — intervention group
Group type: EXPERIMENTAL
Intervention: Walsh and Ogura technique
Number of subjects: 17
Study 10721594 — intervention group
Group type: COMPARATOR
Intervention: Kennedy's surgical approach
Number of subjects: 17
Study 8868968 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy with adolescents
Number of subjects: 0
Study 8868968 — intervention group
Group type: COMPARATOR
Intervention: Controlled outcome studies
Number of subjects: 0
Study 1658652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (5 mg/kg twice a day for one week, followed by 5 mg/kg per day)
Number of subjects: 72
Study 1658652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 1658652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 72
Study 6350071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tioconazole 1% cream applied twice daily for 14 days (pityriasis versicolor) or 28 days (dermatophyte and yeast infections)
Number of subjects: 60
Study 6350071 — intervention group
Group type: COMPARATOR
Intervention: Miconazole 2% cream applied twice daily for 14 days (pityriasis versicolor) or 28 days (dermatophyte and yeast infections)
Number of subjects: 60
Study 6350071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tioconazole for infections with Trichophyton rubrum
Number of subjects: 60
Study 6350071 — intervention group
Group type: COMPARATOR
Intervention: Miconazole for infections with Trichophyton rubrum
Number of subjects: 60
Study 6350071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tioconazole long-term follow-up
Number of subjects: 60
Study 6350071 — intervention group
Group type: COMPARATOR
Intervention: Miconazole long-term follow-up
Number of subjects: 60
Study 31200505 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ)
Number of subjects: 13
Study 31200505 — intervention group
Group type: COMPARATOR
Intervention: Placebo nitrate-depleted BJ (PLA)
Number of subjects: 13
Study 31200505 — intervention group
Group type: COMPARATOR
Intervention: Orange flavored non-caloric drink (OFD)
Number of subjects: 13
Study 31200505 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (BJ, PLA, OFD)
Number of subjects: 13
Study 30272849 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-plus-diet intervention for 12 months
Number of subjects: 180
Study 30272849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 180
Study 27508536 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril (1.5 mg/kg/dose, thrice a day for three days)
Number of subjects: 329
Study 27508536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 27508536 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril
Number of subjects: 329
Study 25205324 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage palate closure
Number of subjects: 48
Study 25205324 — intervention group
Group type: COMPARATOR
Intervention: Early two-stage palate closure
Number of subjects: 48
Study 23082801 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-cooled Nd:YAG laser (1064 nm, 4W, 250-μsec pulse) used in conjunction with supragingival and subgingival debridement (scaling and root planing, SRP)
Number of subjects: 30
Study 23082801 — intervention group
Group type: COMPARATOR
Intervention: Supragingival and subgingival debridement (scaling and root planing, SRP) alone
Number of subjects: 30
Study 23082801 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-cooled Nd:YAG laser (1064 nm, 4W, 250-μsec pulse)
Number of subjects: 30
Study 19246893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fb (grape‐orange‐apricot)
Number of subjects: 32
Study 19246893 — intervention group
Group type: EXPERIMENTAL
Intervention: FbM (Fb with skimmed milk)
Number of subjects: 32
Study 19246893 — intervention group
Group type: EXPERIMENTAL
Intervention: FbMFe (FbM + Fe(II))
Number of subjects: 32
Study 17634494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 9 g/m2 over 3 days continuous infusion
Number of subjects: 326
Study 17634494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 3 g/m2 per day in 3 hours over 3 days
Number of subjects: 326
Study 17634494 — intervention group
Group type: COMPARATOR
Intervention: Standard doxorubicin 75 mg/m2 every 21 days
Number of subjects: 326
Study 14691439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban + heparin
Number of subjects: 57
Study 14691439 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 57
Study 11720197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy regimens (estrogen plus different progestogens)
Number of subjects: 0
Study 11720197 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 11720197 — intervention group
Group type: COMPARATOR
Intervention: Estrogen replacement therapy alone
Number of subjects: 0
Study 11720197 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy for secondary prevention
Number of subjects: 0
Study 9700042 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol Turbuhaler (50, 50, 100, 200, 400 microg)
Number of subjects: 24
Study 9700042 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol Diskhaler (200, 200, 400, 800, 1600 microg)
Number of subjects: 24
Study 9779765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil oral suspension (10 mg/kg) administered in fed condition
Number of subjects: 17
Study 9779765 — intervention group
Group type: COMPARATOR
Intervention: Cefpodoxime proxetil oral suspension (10 mg/kg) administered in fasted condition
Number of subjects: 17
Study 2577461 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzothiadiazine diuretic agents
Number of subjects: 0
Study 2577461 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic receptor-blocking drugs
Number of subjects: 0
Study 2577461 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both drug classes
Number of subjects: 0
Study 889651 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65% halothane with 50% nitrous oxide in oxygen
Number of subjects: 30
Study 889651 — intervention group
Group type: COMPARATOR
Intervention: 0.2% halothane with 50% nitrous oxide in oxygen
Number of subjects: 30
Study 31995683 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 13295
Study 31995683 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 13295
Study 31995683 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening (women)
Number of subjects: 13295
Study 31101685 — intervention group
Group type: COMPARATOR
Intervention: HIE + NT (normothermia)
Number of subjects: 138
Study 31101685 — intervention group
Group type: EXPERIMENTAL
Intervention: HIE + TH (therapeutic hypothermia)
Number of subjects: 138
Study 31101685 — intervention group
Group type: COMPARATOR
Intervention: Control group (without HIE)
Number of subjects: 138
Study 31101685 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak serum bilirubin concentrations at 96 h of age
Number of subjects: 138
Study 28470550 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution infused at a rate of 125 mL/h
Number of subjects: 300
Study 28470550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution infused at a rate of 250 mL/h
Number of subjects: 300
Study 28470550 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution boosted with 5% glucose, infused at a rate of 125 mL/h
Number of subjects: 300